杨林,博士,公司董事会主席,苏州大学唐仲英血液学研究中心特聘教授、博士生导师、西安交大苏州研究院研究生导师、苏州市现代生物制药工程重点实验室副主任、美国MD Anderson Cancer Center兼职教授。中山大学生物医药研究中心博士学位,曾任广州溯源地基因科技有限公司董事长兼首任总经理,拥有20年的癌症遗传学、癌症免疫治疗、生物纳米应用、基因和蛋白质工程等方面的生物医学研究和发展经验和企业管理经验。

 

Lin Yang, Ph.D., Chairman of the Board of PersonGen, Distinguished Professor of Soochow University, Adjunct Professor of MD Anderson Cancer Center, and Deputy Director of Modern Biomedicine R&D Key Lab of Soochow. Dr. Lin Yang obtained his Ph.D. degree from Biopharmaceutical Center at Sun Yat-sen University in 1998, completed his Postdoctoral training from George Whipple Cancer Laboratory at University of Rochester (2001-2003) and MD Anderson Cancer Center (2003-2007) respectively. Dr. Lin Yang identified a novel transcription factor of ZKSCAN3 which plays a critical role in cancer pathobiology, as well as 34 potential chemosensitivity genes. Dr. Lin Yang has more than 20 years of cancer genetics, cancer immunotherapy, genetic and protein engineering research experiences.

 

                                          

杨楠,博士,公司总经理,苏州市现代生物制药工程重点实验室副主任、董事。澳大利亚New Castle大学博士学位,曾任澳大利亚AusBioMed Pty Ltd公司总裁,澳大利亚悉尼大学优秀博士生导师,Westmead儿童医院高级科学家,重大项目负责人,拥有丰富的创业和企业管理经验、以及25年的生物医学项目管理经验。对生物医药的发展具有卓越的洞察力和战略眼光。

 

Nan Yang, Ph.D., Chief of Executive Officer of PersonGen, Director of Modern Biomedicine R&D Key Lab of Soochow. Dr. Nan Yang obtained his Ph.D. degree in Biochemistry from University of New Castle, Australia in 1992 and completed his postdoctoral training in Biochemistry and Human Genetics from John Curtin School of Medical Research at Australian National University (1992-1995). Before Dr. Nan Yang took the position of PersonGen CEO, he was the Senior Lecturer, Discipline of Paediatrics and Child Health, Faculty of Medicine, University of Sydney, Australia; as well as the Team Leader of Actinin and Skeletal Muscle Performance and Function Team at the Institute for Neuroscience and Muscle Research, Children’s Hospital at Westmead, Sydney, Australia. Dr. Nan Yang discovered that ACTN3 R577X genotype influences athletic performance, This association study was cited by Discovery Magazine in January 2004 as one of the “Top 100 Science Stories of 2003” – ranked number 76. Dr. Nan Yang has more than 25 years of human genetics, biomedicine R&D, and project management experiences.

 

 

                                           

  

刘建平,博士,公司副总经理兼化学合成部经理,董事,云南大学教授、博士生导师、曾任云南大学药物研究院副院长 。美国德克萨斯州立大学(奥斯汀)访问学者、澳大利亚国立大学化学研究院博士学位。拥有20余年的天然产物结构修饰及性能研究、药物合成及构效关系研究及天然产物全合成和反应方法学方面的工作发展经验。

 

              

                                          

 

杨文荣,博士,公司副总经理兼医药纳米部经理,西安交大苏州研究员研究生导师、董事。澳大利亚新南威尔士大学博士学位,曾任澳大利亚悉尼大学、澳洲国家显微镜与微量分析中心研究员;拥有20年的纳米材料制备与应用、纳米材料生物医学功能化、肿瘤纳米治疗的研究和发展经验。其研究成果获高达近800次引用。

 

  

 

 

                                       

 

 

 

Make a Free Website with Yola.